| 生物活性 | |||
|---|---|---|---|
| 靶点 | 
 | ||
| 描述 | Trans-2-Phenylcyclopropylamine (2-PCPA) is a time-dependent, mechanism-based irreversible inhibitor of LSD1 with a KI of 242 mM and a kinact of 0.0106 s-1. 2-PCPA shows limited selectivity for human MAOs versus LSD1, with kinact/KI values only 16-fold and 2.4-fold higher for MAO B and MAO A, respectively[3]. 2-PCPA-based inhibitors featuring substitutions on the amino group have emerged, with sub-micromolar affinities toward LSD1 (Lysine-specific demethylase 1) and high selectivities over monoamine oxidases (MAOs)[4]. Mice treated with the antidepressant trans-2-phenylcyclopropylamine (2-PCPA) were protected against diet-induced-obesity, and adiposity was reversed in pre-established diet-induced obese mice. 2-PCPA can reduce obesity by decreasing food intake in the long term while increasing activity in the short-term[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 5.89mL 1.18mL 0.59mL | 29.47mL 5.89mL 2.95mL | 58.94mL 11.79mL 5.89mL | 
| 参考文献 | 
|---|